Skip to main content
NCBI home page
The AAPS Journal logoLink to The AAPS Journal
. 2005 Oct 27;7(3):E728–E738. doi: 10.1208/aapsj070373

Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants

Lankupalle D Jayanthi 1,✉, Sammanda Ramamoorthy 1
PMCID: PMC2751275  PMID: 16353949

Abstract

Synaptic neurotransmission in the central nervous system (CNS) requires the precise control of the duration and the magnitude of neurotransmitter action at specific molecular targets. At the molecular level, neurotransmitter signaling is dynamically regulated by a diverse set of macromolecules including biosynthetic enzymes, secretory proteins, ion channels, pre- and postsynaptic receptors and transporters. Monoamines, 5-hydroxytryptamine or serotonin (5-HT), norepinephrine (NE), and dopamine (DA) play an important modulatory role in the CNS and are involved in numerous physiological functions and pathological conditions. Presynaptic plasma membrane transporters for 5-HT (SERT), NE (NET), and DA (DAT), respectively, control synaptic actions of these monoamines by rapidly clearing the released amine. Monoamine transporters are the sites of action for widely used antidepressants and are high affinity molecular targets for drugs of abuse including cocaine, amphetamine, and 3,4-methylenedioxymetamphetamine (MDMA) “Ecstasy”. Monoamine transporters also serve as molecular gateways for neurotoxins. Emerging evidence indicates that regulation of transporter function and surface expression can be rapidly modulated by “intrinsic” transporter activity itself, and antidepressant and psychostimulant drugs that block monoamine transport have a profound effect on transporter regulation. Therefore, disregulations in the functioning of monoamine transporters may underlie many disorders of transmitter imbalance such as depression, attention deficit hyperactivity disorder, and schizophrenia. This review integrates recent progress in understanding the molecular mechanisms of monoamine transporter regulation, in particular, posttranscriptional regulation by phosphorylation and trafficking linked to cellular protein kinases, protein phosphatases, and transporter interacting proteins. The review also discusses the possible role of psychostimulants and antidepressants in influencing monoamine transport regulation.

Key words: phosphorylation, trafficking, interacting proteins, substrates, and ligands

Full Text

The Full Text of this article is available as a PDF (203.1 KB).

References

  • 1.Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res. 2001;25:487–495. doi: 10.1111/j.1530-0277.2001.tb02240.x. [DOI] [PubMed] [Google Scholar]
  • 2.Hahn MK, Blakely RD. Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2002;2:217–235. doi: 10.1038/sj.tpj.6500106. [DOI] [PubMed] [Google Scholar]
  • 3.Rocha BA, Fumagalli F, Gainetdinov RR, et al. Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci. 1998;1:132–137. doi: 10.1038/1152. [DOI] [PubMed] [Google Scholar]
  • 4.Sora I, Hall FS, Andrews AM, et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA. 2001;98:5300–5305. doi: 10.1073/pnas.091039298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Flattem NL, Blakely RD. Modified structure of the human serotonin transporter promoter. Mol Psychiatry. 2000;5:110–115. doi: 10.1038/sj.mp.4000585. [DOI] [PubMed] [Google Scholar]
  • 6.McCauley JL, Olson LM, Dowd M, et al. Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid-compulsive subset of autism. Am J Med Genet B Neuropsychiatr Genet. 2004;127:104–112. doi: 10.1002/ajmg.b.20151. [DOI] [PubMed] [Google Scholar]
  • 7.Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003;8:895–936. doi: 10.1038/sj.mp.4001415. [DOI] [PubMed] [Google Scholar]
  • 8.Kilic F, Murphy DL, Rudnick G. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Pharmacol. 2003;64:440–446. doi: 10.1124/mol.64.2.440. [DOI] [PubMed] [Google Scholar]
  • 9.Astier B, Van Bockstaele EJ, Aston-Jones G, Pieribone VA. Anatomical evidence for multiple pathways leading from the rostral ventrolateral medulla (nucleus paragigantocellularis) to the locus coeruleus in rat. Neurosci Lett. 1990;118:141–146. doi: 10.1016/0304-3940(90)90612-D. [DOI] [PubMed] [Google Scholar]
  • 10.Pavcovich LA, Cancela LM, Volosin M, Molina VA, Ramirez OA. Chronic stress-induced changes in locus coeruleus neuronal activity. Brain Res Bull. 1990;24:293–296. doi: 10.1016/0361-9230(90)90219-P. [DOI] [PubMed] [Google Scholar]
  • 11.Holden JE, Naleway E. Microinjection of carbachol in the lateral hypothalamus produces opposing actions on nociception mediated by alpha(1)- and alpha(2)-adrenoceptors. Brain Res. 2001;911:27–36. doi: 10.1016/S0006-8993(01)02567-7. [DOI] [PubMed] [Google Scholar]
  • 12.Jasmin L, Tien D, Weinshenker D. The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc Natl Acad Sci USA. 2002;99:1029–1034. doi: 10.1073/pnas.012598599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Axelrod J, Kopin IJ. The uptake, storage, release, and metabolism of noradrenaline in sympathetice nerves. Prog Brain Res. 1969;31:21–32. doi: 10.1016/S0079-6123(08)63224-0. [DOI] [PubMed] [Google Scholar]
  • 14.Iversen LL. Uptake processes for biogenic amines. In: Iversen I, editor. Handbook of Psychopharmacology. 3rd ed. New York, NY: Prenum Press; 1978. pp. 381–442. [Google Scholar]
  • 15.Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991;350:350–354. doi: 10.1038/350350a0. [DOI] [PubMed] [Google Scholar]
  • 16.Amara SG, Arriza JL. Neurotransmitter transporters: three distinct gene families. Curr Opin Neurobiol. 1993;3:337–344. doi: 10.1016/0959-4388(93)90126-J. [DOI] [PubMed] [Google Scholar]
  • 17.Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:8451–8458. doi: 10.1523/JNEUROSCI.17-21-08451.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ganguly PK, Dhalla KS, Imes IR, Beamish RE, Dhall NS. Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res. 1986;59:684–693. doi: 10.1161/01.res.59.6.684. [DOI] [PubMed] [Google Scholar]
  • 19.Merlet P, Dubois-Rande J-L, Adnot S, et al. Myocardial b-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992;19:10–16. doi: 10.1097/00005344-199201000-00002. [DOI] [PubMed] [Google Scholar]
  • 20.Robertson D, Flattem N, Tellioglu T, et al. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 2001;940:527–543. doi: 10.1111/j.1749-6632.2001.tb03703.x. [DOI] [PubMed] [Google Scholar]
  • 21.Xu F, Gainetdinov RR, Wetsel WC, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci. 2000;3:465–471. doi: 10.1038/74839. [DOI] [PubMed] [Google Scholar]
  • 22.Thompson AC, Zapata A, Justice JB, Vaughan RA, Sharpe LG, Shippenberg TS. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci. 2000;20:9333–9340. doi: 10.1523/JNEUROSCI.20-24-09333.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci. 2003;23:4470–4478. doi: 10.1523/JNEUROSCI.23-11-04470.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237–260. doi: 10.1146/annurev.pharmtox.41.1.237. [DOI] [PubMed] [Google Scholar]
  • 25.Greengard P. The neurobiology of slow synaptic transmission. Science. 2001;294:1024–1030. doi: 10.1126/science.294.5544.1024. [DOI] [PubMed] [Google Scholar]
  • 26.Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci. 1995;15:4102–4108. doi: 10.1523/JNEUROSCI.15-05-04102.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sora I, Wichems C, Takahashi N, et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA. 1998;95:7699–7704. doi: 10.1073/pnas.95.13.7699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Rioux A, Fabre V, Lesch KP, et al. Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett. 1999;262:113–116. doi: 10.1016/S0304-3940(99)00049-X. [DOI] [PubMed] [Google Scholar]
  • 29.Carboni E, Spielewoy C, Vacca C, Nosten-Bertrand M, Giros B, Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci. 2001;21:1–4. doi: 10.1523/JNEUROSCI.21-09-j0001.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kula NS, Baldessarini RJ. Lack of increase in dopamine transporter binding or functions in rat brain tissue after treatment with blockers of neuronal uptake of dopamine. Neuropharmacology. 1991;30:89–92. doi: 10.1016/0028-3908(91)90047-F. [DOI] [PubMed] [Google Scholar]
  • 31.Giros B, El Mestikawy S, Godinot N, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol. 1992;42:383–390. [PubMed] [Google Scholar]
  • 32.Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606–612. doi: 10.1038/379606a0. [DOI] [PubMed] [Google Scholar]
  • 33.Eichelman BS. Neurochemical and psychopharmacologic aspects of aggressive behavior. Annu Rev Med. 1990;41:149–158. doi: 10.1146/annurev.me.41.020190.001053. [DOI] [PubMed] [Google Scholar]
  • 34.Comings DE. Clinical and molecular genetics of ADHD and Tourette syndrome: two related polygenic disorders. Ann NY Acad Sci. 2001;931:50–83. doi: 10.1111/j.1749-6632.2001.tb05773.x. [DOI] [PubMed] [Google Scholar]
  • 35.Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002;163:102–105. doi: 10.1007/s00213-002-1166-3. [DOI] [PubMed] [Google Scholar]
  • 36.Miller GM, De La Garza RD, Novak MA, Madras BK. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperativity disorder and other neuropsychiatric disorders. Mol Psychiatry. 2001;6:50–58. doi: 10.1038/sj.mp.4000809. [DOI] [PubMed] [Google Scholar]
  • 37.Lin Z, Uhl GR. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol. 2002;61:885–891. doi: 10.1124/mol.61.4.885. [DOI] [PubMed] [Google Scholar]
  • 38.Reith MEA, Meisler BE, Sershen H, Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol. 1986;35:1123–1129. doi: 10.1016/0006-2952(86)90148-6. [DOI] [PubMed] [Google Scholar]
  • 39.Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–677. doi: 10.1146/annurev.pa.33.040193.003231. [DOI] [PubMed] [Google Scholar]
  • 40.Bengel D, Murphy DL, Andrews AM, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxym etamphetamine (“ecstasy”) in serotonin transporter-deficient mice. Mol Pharmacol. 1998;53:649–655. doi: 10.1124/mol.53.4.649. [DOI] [PubMed] [Google Scholar]
  • 41.Rocha BA, Scearce-Levie K, Lucas JJ, et al. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature. 1998;393:175–178. doi: 10.1038/30259. [DOI] [PubMed] [Google Scholar]
  • 42.Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63. doi: 10.1126/science.278.5335.58. [DOI] [PubMed] [Google Scholar]
  • 43.Pierce RC, Kalivas PW. Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. J Neurosci. 1997;17:3254–3261. doi: 10.1523/JNEUROSCI.17-09-03254.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Cases O, Lebrand C, Giros B, et al. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. J Neurosci. 1998;18:6914–6927. doi: 10.1523/JNEUROSCI.18-17-06914.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Pan Y, Gembom E, Peng W, Lesch KP, Mossner R, Simantov R. Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice. Brain Res Dev Brain Res. 2001;126:125–129. doi: 10.1016/S0165-3806(00)00145-0. [DOI] [PubMed] [Google Scholar]
  • 46.Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22:389–395. doi: 10.1523/JNEUROSCI.22-02-00389.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ramamoorthy S, Cool DR, Mahesh VB, et al. Regulation of the human serotonin transporter: cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J Biol Chem. 1993;268:21626–21631. [PubMed] [Google Scholar]
  • 48.Ramamoorthy JD, Ramamoorthy S, Papapetropoulos A, Catravas JD, Leibach FH, Ganapathy V. Cyclic AMP-independent up-regulation of the human serotonin transporter by staurosporine in choriocarcinoma cells. J Biol Chem. 1995;270:17189–17195. doi: 10.1074/jbc.270.29.17189. [DOI] [PubMed] [Google Scholar]
  • 49.Ramamoorthy S, Ramamoorthy JD, Prasad P, et al. Regulation of the human serotonin transporter by interleukin-1b. Biochem Biophys Res Commun. 1995;216:560–567. doi: 10.1006/bbrc.1995.2659. [DOI] [PubMed] [Google Scholar]
  • 50.Blakely RD, Ramamoorthy S, Qian Y, Schroeter S, Bradley C. Regulation of antidepressant-sensitive serotonin transporters. In: Reith MEA, editor. Neurotransmitter Transporters: Structure, Function, and Regulation. Totowa, NJ: Humana Press; 1997. pp. 29–72. [Google Scholar]
  • 51.Bradley CC. Structure, Regulation, and Expression of the Human Serotonin Transporter Gene [Doctoral dissertation] Atlanta, GA: Anatomy and Cell Biology, Emory University; 1998. [Google Scholar]
  • 52.Ramamoorthy S. Regulation of monoamine transporters: Regulated phosphorylation, dephosphorylation, and trafficking. Totowa, NJ: Humana Press Inc; 2002. [Google Scholar]
  • 53.Wakade AR, Wakade TD, Poosch M, Bannon MJ. Noradrenaline transport and transporter mRNA of rat chromaffin cells are controlled by dexamethasone and nerve growth factor. J Physiol. 1996;494:67–75. doi: 10.1113/jphysiol.1996.sp021476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res. 1993;602:161–164. doi: 10.1016/0006-8993(93)90258-O. [DOI] [PubMed] [Google Scholar]
  • 55.Meyer JS, Shearman LP, Collins LM. Monoamine transporters and the neurobehavioral teratology of cocaine. Pharmacol Biochem Behav. 1996;55:585–593. doi: 10.1016/S0091-3057(96)00280-8. [DOI] [PubMed] [Google Scholar]
  • 56.Ikeda T, Kitayama S, Morita K, Dohi T. Nerve growth factor down-regulates the expression of norepinephrine transporter in rat pheochromocytoma (PC12) cells. Brain Res Mol Brain Res. 2001;86:90–100. doi: 10.1016/S0169-328X(00)00272-2. [DOI] [PubMed] [Google Scholar]
  • 57.Fang Y, Ronnekleiv OK. Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain. J Neurosci. 1999;19:8966–8978. doi: 10.1523/JNEUROSCI.19-20-08966.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Shearman LP, Meyer JS. Cocaine up-regulates norepinephrine transporter binding in the rat placenta. Eur J Pharmacol. 1999;386:1–6. doi: 10.1016/S0014-2999(99)00624-X. [DOI] [PubMed] [Google Scholar]
  • 59.Macey DJ, Smith HR, Nader MA, Porrino LJ. Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity in the bed nucleus of the stria terminalis of the rhesus monkey. J Neurosci. 2003;23:12–16. doi: 10.1523/JNEUROSCI.23-01-00012.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Li LB, Chen N, Ramamoorthy S, et al. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem. 2004;279:21012–21020. doi: 10.1074/jbc.M311972200. [DOI] [PubMed] [Google Scholar]
  • 61.Vaughan RA, Huff RA, Uhl GR, Kuhar MJ. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem. 1997;272:15541–15546. doi: 10.1074/jbc.272.24.15541. [DOI] [PubMed] [Google Scholar]
  • 62.Ramamoorthy S, Giovanetti E, Qian Y, Blakely RD. Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem. 1998;273:2458–2466. doi: 10.1074/jbc.273.4.2458. [DOI] [PubMed] [Google Scholar]
  • 63.Jayanthi LD, Samuvel DJ, Ramamoorthy S. Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters: evidence for localization in lipid rafts and lipid raft mediated internalization. J Biol Chem. 2004;279:19315–19326. doi: 10.1074/jbc.M311172200. [DOI] [PubMed] [Google Scholar]
  • 64.Apparsundaram S, Galli A, DeFelice LJ, Hartzell HC, Blakely RD. Acute regulation of norepinephrine transport. I. PKC-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther. 1998;287:733–743. [PubMed] [Google Scholar]
  • 65.Apparsundaram S, Schroeter S, Blakely RD. Acute regulation of norepinephrine transport. II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther. 1998;287:744–751. [PubMed] [Google Scholar]
  • 66.Bauman AL, Apparsundaram S, Ramamoorthy S, Wadzinski BE, Vaughan RA, Blakely RD. Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J Neurosci. 2000;20:7571–7578. doi: 10.1523/JNEUROSCI.20-20-07571.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Qian Y, Galli A, Ramamoorthy S, Risso S, DeFelice LJ, Blakely RD. Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci. 1997;17:45–57. doi: 10.1523/JNEUROSCI.17-01-00045.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kitayama S, Dohi T, Uhl G. Phorbol esters alter functions of the expressed dopamine transporter. Eur J Pharmacol. 1994;268:115–119. doi: 10.1016/0922-4106(94)90180-5. [DOI] [PubMed] [Google Scholar]
  • 69.Zhang L, Coffey LL, Reith MEA. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol. 1997;53:677–688. doi: 10.1016/S0006-2952(96)00898-2. [DOI] [PubMed] [Google Scholar]
  • 70.Daniels G, Amara SG. Regulation trafficking of the human dopamine transporter clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem. 1999;274:35794–35801. doi: 10.1074/jbc.274.50.35794. [DOI] [PubMed] [Google Scholar]
  • 71.Melikian HE, Buckley KM. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci. 1999;19:7699–7710. doi: 10.1523/JNEUROSCI.19-18-07699.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Loder MK, Melikian HE. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem. 2003;278:22168–22174. doi: 10.1074/jbc.M301845200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Sorkina T, Hoover BR, Zahniser NR, Sorkin A. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic. 2005;6:157–170. doi: 10.1111/j.1600-0854.2005.00259.x. [DOI] [PubMed] [Google Scholar]
  • 74.Holton KL, Loder MK, Melikian HE. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci. 2005;8:881–888. doi: 10.1038/nn1478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci. 2005;25:29–41. doi: 10.1523/JNEUROSCI.3754-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ramamoorthy S, Prasa PD, Kulanthaivel P, Leibach FH, Blakely RD, Ganapathy V. Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncitiotrophoblast. Biochemistry. 1993;32:1346–1353. doi: 10.1021/bi00056a021. [DOI] [PubMed] [Google Scholar]
  • 77.Ramamoorthy JD, Ramamoorthy S, Leibach FH, Ganapathy V. Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol. 1995;173:1782–1787. doi: 10.1016/0002-9378(95)90427-1. [DOI] [PubMed] [Google Scholar]
  • 78.Jayanthi LD, Prasad PD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathy V. Sodium- and chloride-dependent, cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. Biochemistry. 1993;32:12178–12185. doi: 10.1021/bi00096a030. [DOI] [PubMed] [Google Scholar]
  • 79.Chamberlain LH, Gould GW. The vesicle- and target-SNARE proteins that mediate Glut4 vesicle fusion are localized in detergent-insoluble lipid rafts present on distinct intracellular membranes. J Biol Chem. 2002;277:49750–49754. doi: 10.1074/jbc.M206936200. [DOI] [PubMed] [Google Scholar]
  • 80.Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. doi: 10.1038/35036052. [DOI] [PubMed] [Google Scholar]
  • 81.Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572. doi: 10.1038/42408. [DOI] [PubMed] [Google Scholar]
  • 82.Parton RG, Richards AA. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic. 2003;4:724–738. doi: 10.1034/j.1600-0854.2003.00128.x. [DOI] [PubMed] [Google Scholar]
  • 83.Apparsundaram S, Sung U, Price RD, Blakely RD. Trafficking-dependent and- independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J Pharmacol Exp Ther. 2001;299:666–677. [PubMed] [Google Scholar]
  • 84.Carvelli L, Moron JA, Kahlig KM, et al. PI 3-kinase regulation of dopamine uptake. J Neurochem. 2002;81:859–869. doi: 10.1046/j.1471-4159.2002.00892.x. [DOI] [PubMed] [Google Scholar]
  • 85.Moron JA, Zakharova I, Ferrer JV, et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci. 2003;23:8480–8488. doi: 10.1523/JNEUROSCI.23-24-08480.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Zhu CB, Hewlett WA, Feoktistov I, Biaggioni I, Blakely RD. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol. 2004;65:1462–1474. doi: 10.1124/mol.65.6.1462. [DOI] [PubMed] [Google Scholar]
  • 87.Chaouloff F, Berton O, Mormede P. Serotonin and stress. Neuropsychopharmacology. 1999;21:28S–32S. doi: 10.1016/S0893-133X(99)00008-1. [DOI] [PubMed] [Google Scholar]
  • 88.Miller KJ, Hoffman BJ. Adenosine A3 receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem. 1994;269:27351–27356. [PubMed] [Google Scholar]
  • 89.Huff RA, Vaughan RA, Kuhar MJ, Uhl GR. Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J Neurochem. 1997;68:225–232. doi: 10.1046/j.1471-4159.1997.68010225.x. [DOI] [PubMed] [Google Scholar]
  • 90.Ramamoorthy S, Blakely RD. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 1999;285:763–766. doi: 10.1126/science.285.5428.763. [DOI] [PubMed] [Google Scholar]
  • 91.Foster JD, Pananusorn B, Vaughan RA. Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem. 2002;277:25178–25186. doi: 10.1074/jbc.M200294200. [DOI] [PubMed] [Google Scholar]
  • 92.Bonisch H, Hammermann R, Bruss M. Role of protein kinase C and second messengers in regulation of the norepinephrine transporter. Adv Pharmacol. 1998;42:183–186. doi: 10.1016/S1054-3589(08)60723-1. [DOI] [PubMed] [Google Scholar]
  • 93.Whitworth TL, Quick MW. Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma-aminobutyric acid derivatives. Biochem Soc Trans. 2001;29:736–741. doi: 10.1042/BST0290736. [DOI] [PubMed] [Google Scholar]
  • 94.Granas C, Ferrer J, Loland CJ, Javitch JA, Gether U. N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J Biol Chem. 2003;278:4990–5000. doi: 10.1074/jbc.M205058200. [DOI] [PubMed] [Google Scholar]
  • 95.Lin Z, Zhang PW, Zhu X, et al. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem. 2003;278:20162–20170. doi: 10.1074/jbc.M209584200. [DOI] [PubMed] [Google Scholar]
  • 96.Doolen S, Zahniser NR. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes. J Pharmacol Exp Ther. 2001;296:931–938. [PubMed] [Google Scholar]
  • 97.Law RM, Stafford A, Quick MW. Functional regulation of gamma-aminobutyric acid transporters by direct tyrosine phosphorylation. J Biol Chem. 2000;275:23986–23991. doi: 10.1074/jbc.M910283199. [DOI] [PubMed] [Google Scholar]
  • 98.Whitworth TL, Quick MW. Substrate-induced regulation of gamma-aminobutyric acid transporter trafficking requires tyrosine phosphorylation. J Biol Chem. 2001;276:42932–42937. doi: 10.1074/jbc.M107638200. [DOI] [PubMed] [Google Scholar]
  • 99.Quick MW, Hu J, Wang D, Zhang HY. Regulation of a gamma-aminobutyric acid transporter by reciprocal tyrosine and serine phosphorylation. J Biol Chem. 2004;279:15961–15967. doi: 10.1074/jbc.M306924200. [DOI] [PubMed] [Google Scholar]
  • 100.Sung U, Apparsundaram S, Galli A, et al. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci. 2003;23:1697–1709. doi: 10.1523/JNEUROSCI.23-05-01697.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Bauman PA, Blakely RD. Determinants within the C-terminus of the human norepinephrine transporter dictate transporter trafficking, stability, and activity. Arch Biochem Biophys. 2002;404:80–91. doi: 10.1016/S0003-9861(02)00232-1. [DOI] [PubMed] [Google Scholar]
  • 102.Uhl GR, Lin Z. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol. 2003;479:71–82. doi: 10.1016/j.ejphar.2003.08.058. [DOI] [PubMed] [Google Scholar]
  • 103.Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, Javitch JA. Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol. 2003;479:3–12. doi: 10.1016/j.ejphar.2003.08.052. [DOI] [PubMed] [Google Scholar]
  • 104.Loland CJ, Granas C, Javitch JA, Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J Biol Chem. 2004;279:3228–3238. doi: 10.1074/jbc.M304755200. [DOI] [PubMed] [Google Scholar]
  • 105.Fornes A, Nunez E, Aragon C, Lopez-Corcuera B. The second intracellular loop of the glycine transporter 2 contains crucial residues for glycine transport and phorbol ester-induced regulation. J Biol Chem. 2004;279:22934–22943. doi: 10.1074/jbc.M401337200. [DOI] [PubMed] [Google Scholar]
  • 106.Deken SL, Beckman ML, Boos L, Quick MW. Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A. Nat Neurosci. 2000;3:998–1003. doi: 10.1038/79939. [DOI] [PubMed] [Google Scholar]
  • 107.Horton N, Quick MW. Syntaxin 1A up-regulates GABA transporter expression by subcellular redistribution. Mol Membr Biol. 2001;18:39–44. doi: 10.1080/09687680010029383. [DOI] [PubMed] [Google Scholar]
  • 108.Wang D, Deken SL, Whitworth TL, Quick MW. Syntaxin 1A inhibits GABA flux, efflux, and exchange mediated by the rat brain GABA transporter GAT1. Mol Pharmacol. 2003;64:905–913. doi: 10.1124/mol.64.4.905. [DOI] [PubMed] [Google Scholar]
  • 109.Haase J, Killian AM, Magnani F, Williams C. Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans. 2001;29:722–728. doi: 10.1042/BST0290722. [DOI] [PubMed] [Google Scholar]
  • 110.Torres GE, Yao WD, Mohn AR, et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001;30:121–134. doi: 10.1016/S0896-6273(01)00267-7. [DOI] [PubMed] [Google Scholar]
  • 111.Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001;15:916–926. doi: 10.1096/fj.00-0334com. [DOI] [PubMed] [Google Scholar]
  • 112.Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–2047. doi: 10.1126/science.276.5321.2045. [DOI] [PubMed] [Google Scholar]
  • 113.Wersinger C, Vernier P, Sidhu A. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Biochemistry. 2004;43:1242–1253. doi: 10.1021/bi035308s. [DOI] [PubMed] [Google Scholar]
  • 114.Carneiro AM, Ingram SL, Beaulieu JM, et al. The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J Neurosci. 2002;22:7045–7054. doi: 10.1523/JNEUROSCI.22-16-07045.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Saunders C, Ferrer JV, Shi L, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850–6855. doi: 10.1073/pnas.110035297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Daws LC, Callaghan PD, Moron JA, et al. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun. 2002;290:1545–1550. doi: 10.1006/bbrc.2002.6384. [DOI] [PubMed] [Google Scholar]
  • 117.Little KY, Elmer LW, Zhong H, Scheys JO, Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol Pharmacol. 2002;61:436–445. doi: 10.1124/mol.61.2.436. [DOI] [PubMed] [Google Scholar]
  • 118.Bernstein EM, Quick MW. Regulation of gamma-aminobutyric acid (GABA) transporters by extracellular GABA. J Biol Chem. 1999;274:889–895. doi: 10.1074/jbc.274.2.889. [DOI] [PubMed] [Google Scholar]
  • 119.Munir M, Correale DM, Robinson MB. Substrate-induced up-regulation of Na(+)-dependent glutamate transport activity. Neurochem Int. 2000;37:147–162. doi: 10.1016/S0197-0186(00)00018-8. [DOI] [PubMed] [Google Scholar]
  • 120.Quick MW. Substrates regulate gamma-aminobutyric acid transporters in a syntaxin 1A-dependent manner. Proc Natl Acad Sci USA. 2002;99:5686–5691. doi: 10.1073/pnas.082712899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Hahn MK, Mazei-Robison M, Blakely RD. Single nucleotide polymorphisms in the human norepinephrine transporter gene impact expression, trafficking, antidepressant interaction and protein kinase C regulation. Mol Pharmacol. 2005;68:457–466. doi: 10.1124/mol.105.011270. [DOI] [PubMed] [Google Scholar]
  • 122.Prasad HC, Zhu C, McCauley JL, et al. Human serotonin transporter variants display selective insensitivity to protein kinase G and p38 mitogen activated kinase. Proc Natl Acad Sci USA. 2005;102:11545–11550. doi: 10.1073/pnas.0501432102. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES